Wonik（A032940）株式概要ウォンイク・コーポレーションは、韓国で半導体、貿易・流通、金融、化粧品、IT・電子部品、ロボット、レジャー事業に従事している。 詳細A032940 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6報酬株価収益率（ 10.8 x）は、 Healthcare業界平均（ 19.4 x）を下回っています。リスク分析過去5年間で収益は年間47%減少しました。 財務結果に影響を与える大きな一時的項目 意味のある時価総額がありません ( ₩96B )利益率(6.3%)は昨年より低い(19.7%) +1 さらなるリスクすべてのリスクチェックを見るA032940 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW481,989 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA481,989 investors already sharing narrativesYour Fair Value₩Current Price₩5.60k17.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-48b262b2016201920222025202620282031Revenue ₩261.6bEarnings ₩16.4bAdvancedSet Fair ValueView all narrativesWonik Corporation 競合他社METACARESymbol: KOSE:A118000Market cap: ₩21.1bHanmi ScienceSymbol: KOSE:A008930Market cap: ₩2.4tCG MedTechLtdSymbol: KOSDAQ:A056090Market cap: ₩94.3bMeta BiomedSymbol: KOSDAQ:A059210Market cap: ₩100.1b価格と性能株価の高値、安値、推移の概要Wonik過去の株価現在の株価₩5,600.0052週高値₩17,800.0052週安値₩4,215.00ベータ1.391ヶ月の変化-8.20%3ヶ月変化-47.17%1年変化-12.64%3年間の変化56.86%5年間の変化6.06%IPOからの変化12.45%最新ニュースValuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩4,470, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 22% over the past three years.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,760, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 19x in the Healthcare industry in Asia. Total returns to shareholders of 103% over the past three years.New Risk • Jun 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 47% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.3% net profit margin).Valuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩7,040, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 19x in the Healthcare industry in Asia. Total returns to shareholders of 75% over the past three years.分析記事 • May 28We Think That There Are More Issues For Wonik (KOSDAQ:032940) Than Just Sluggish EarningsLast week's earnings announcement from Wonik Corporation ( KOSDAQ:032940 ) was disappointing to investors, with a...New Risk • May 19New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩141.7b (US$94.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 46% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.6% net profit margin). Market cap is less than US$100m (₩141.7b market cap, or US$94.0m).最新情報をもっと見るRecent updatesValuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩4,470, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 22% over the past three years.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,760, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 19x in the Healthcare industry in Asia. Total returns to shareholders of 103% over the past three years.New Risk • Jun 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 47% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.3% net profit margin).Valuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩7,040, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 19x in the Healthcare industry in Asia. Total returns to shareholders of 75% over the past three years.分析記事 • May 28We Think That There Are More Issues For Wonik (KOSDAQ:032940) Than Just Sluggish EarningsLast week's earnings announcement from Wonik Corporation ( KOSDAQ:032940 ) was disappointing to investors, with a...New Risk • May 19New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩141.7b (US$94.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 46% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.6% net profit margin). Market cap is less than US$100m (₩141.7b market cap, or US$94.0m).Valuation Update With 7 Day Price Move • May 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩9,520, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 140% over the past three years.Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩10,280, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 163% over the past three years.New Risk • Apr 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 7.6% Last year net profit margin: 15% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 46% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.6% net profit margin).お知らせ • Mar 17Wonik Corporation, Annual General Meeting, Mar 31, 2026Wonik Corporation, Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: av room, 20, pangyo-ro 255beon-gil, bundang-gu, gyeonggi-do, seongnam South KoreaValuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to ₩9,410, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 124% over the past three years.分析記事 • Feb 10Wonik's (KOSDAQ:032940) Returns On Capital Not Reflecting Well On The BusinessThere are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 32%After last week's 32% share price gain to ₩13,940, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 19x in the Healthcare industry in Asia. Total returns to shareholders of 240% over the past three years.分析記事 • Dec 30Wonik Corporation (KOSDAQ:032940) Surges 47% Yet Its Low P/S Is No Reason For ExcitementWonik Corporation ( KOSDAQ:032940 ) shareholders have had their patience rewarded with a 47% share price jump in the...New Risk • Dec 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 38% per year over the past 5 years. Minor Risk Large one-off items impacting financial results.分析記事 • Dec 26We Think Wonik (KOSDAQ:032940) Is Taking Some Risk With Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Nov 21Shareholders In Wonik (KOSDAQ:032940) Should Look Beyond Earnings For The Full StoryThe latest earnings release from Wonik Corporation ( KOSDAQ:032940 ) disappointed investors. We did some analysis and...Reported Earnings • Nov 20Third quarter 2025 earnings released: EPS: ₩455 (vs ₩295 in 3Q 2024)Third quarter 2025 results: EPS: ₩455 (up from ₩295 in 3Q 2024). Revenue: ₩39.6b (up 18% from 3Q 2024). Net income: ₩8.28b (up 55% from 3Q 2024). Profit margin: 21% (up from 16% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩8,720, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 144% over the past three years.分析記事 • Oct 27The Market Lifts Wonik Corporation (KOSDAQ:032940) Shares 40% But It Can Do MoreThe Wonik Corporation ( KOSDAQ:032940 ) share price has done very well over the last month, posting an excellent gain...Valuation Update With 7 Day Price Move • Oct 27Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩9,300, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 207% over the past three years.分析記事 • Oct 24The Returns On Capital At Wonik (KOSDAQ:032940) Don't Inspire ConfidenceIf you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...分析記事 • Aug 28Is Wonik (KOSDAQ:032940) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩6,980, the stock trades at a trailing P/E ratio of 4.8x. Average trailing P/E is 43x in the Healthcare industry in South Korea. Total returns to shareholders of 88% over the past three years.New Risk • Aug 27New major risk - Revenue and earnings growthEarnings have declined by 34% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 34% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩116.3b market cap, or US$83.4m).分析記事 • Jul 31Slammed 32% Wonik Corporation (KOSDAQ:032940) Screens Well Here But There Might Be A CatchThe Wonik Corporation ( KOSDAQ:032940 ) share price has softened a substantial 32% over the previous 30 days, handing...分析記事 • Jul 23Returns On Capital At Wonik (KOSDAQ:032940) Paint A Concerning PictureIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,710, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 111% over the past three years.分析記事 • May 29Fewer Investors Than Expected Jumping On Wonik Corporation (KOSDAQ:032940)You may think that with a price-to-sales (or "P/S") ratio of 0.6x Wonik Corporation ( KOSDAQ:032940 ) is a stock worth...Valuation Update With 7 Day Price Move • May 29Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩4,620, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 39x in the Healthcare industry in South Korea. Negligible returns to shareholders over past three years.New Risk • May 23New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 122% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩68.0b market cap, or US$49.5m).分析記事 • Apr 01There May Be Underlying Issues With The Quality Of Wonik's (KOSDAQ:032940) EarningsWonik Corporation's ( KOSDAQ:032940 ) robust earnings report didn't manage to move the market for its stock. We did...お知らせ • Mar 13Wonik Corporation, Annual General Meeting, Mar 31, 2025Wonik Corporation, Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: av room, 20, pangyo-ro 255beon-gil, bundang-gu, gyeonggi-do, seongnam South Korea分析記事 • Feb 21Market Might Still Lack Some Conviction On Wonik Corporation (KOSDAQ:032940) Even After 35% Share Price BoostWonik Corporation ( KOSDAQ:032940 ) shareholders have had their patience rewarded with a 35% share price jump in the...分析記事 • Feb 21Market Might Still Lack Some Conviction On Wonik Corporation (KOSDAQ:032940) Even After 35% Share Price BoostWonik Corporation ( KOSDAQ:032940 ) shareholders have had their patience rewarded with a 35% share price jump in the...New Risk • Feb 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩85.0b market cap, or US$59.3m).New Risk • Dec 09New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩56.4b market cap, or US$39.6m).New Risk • Nov 22New major risk - Revenue and earnings growthEarnings have declined by 8.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩61.8b market cap, or US$44.1m).分析記事 • Nov 01The Market Doesn't Like What It Sees From Wonik Corporation's (KOSDAQ:032940) Revenues YetWhen you see that almost half of the companies in the Healthcare industry in Korea have price-to-sales ratios (or...お知らせ • Aug 22Horizon Ltd. acquired an additional 38.18% stake in Wonik Corporation (KOSDAQ:A032940) from Lee Yong Han.Horizon Ltd. acquired an additional 38.18% stake in Wonik Corporation (KOSDAQ:A032940) on August 20, 2024.Horizon now holds 46.33% stake in Wonik. The transaction will be financed through equity investment of KRW 5 billion and senior debt of KRW 21.29 billion. Horizon Ltd. completed the acquisition of an additional 38.18% stake in Wonik Corporation (KOSDAQ:A032940) from Lee Yong Han on August 20, 2024.分析記事 • Aug 12Is Wonik (KOSDAQ:032940) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jun 18Wonik Corporation's (KOSDAQ:032940) Price Is Right But Growth Is Lacking After Shares Rocket 42%Wonik Corporation ( KOSDAQ:032940 ) shareholders have had their patience rewarded with a 42% share price jump in the...分析記事 • May 21Estimating The Fair Value Of Wonik Corporation (KOSDAQ:032940)Key Insights Wonik's estimated fair value is ₩4,480 based on 2 Stage Free Cash Flow to Equity With ₩5,120 share price...New Risk • May 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (₩93.1b market cap, or US$68.5m).Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩4,375, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 24x in the Healthcare industry in Asia. Total loss to shareholders of 6.5% over the past three years.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 1 independent director (6 non-independent directors). Chairman Yong-Han Lee was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jun 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩3,565, the stock trades at a trailing P/E ratio of 2.6x. Average trailing P/E is 17x in the Healthcare industry in Asia. Total loss to shareholders of 9.9% over the past three years.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 1 independent director (6 non-independent directors). Chairman Yong-Han Lee was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Buying Opportunity • Feb 15Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 5.5%. The fair value is estimated to be ₩5,083, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.0% per annum over the last 3 years. The company has become profitable over the last year.Buying Opportunity • Jan 25Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be ₩5,071, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.0% per annum over the last 3 years. The company has become profitable over the last year.分析記事 • May 03I Ran A Stock Scan For Earnings Growth And Wonik (KOSDAQ:032940) Passed With EaseFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Is New 90 Day High Low • Feb 26New 90-day low: ₩4,265The company is down 3.0% from its price of ₩4,395 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 9.0% over the same period.分析記事 • Feb 21Reflecting on Wonik's (KOSDAQ:032940) Share Price Returns Over The Last Five YearsWhile not a mind-blowing move, it is good to see that the Wonik Corporation ( KOSDAQ:032940 ) share price has gained...Is New 90 Day High Low • Jan 26New 90-day high: ₩5,150The company is up 51% from its price of ₩3,415 on 28 October 2020. The South Korean market is up 36% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 72% over the same period.分析記事 • Jan 25Is Wonik (KOSDAQ:032940) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Jan 07New 90-day high: ₩5,020The company is up 44% from its price of ₩3,480 on 08 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 56% over the same period.分析記事 • Dec 29Wonik Corporation (KOSDAQ:032940) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?Wonik's (KOSDAQ:032940) stock is up by a considerable 36% over the past three months. But the company's key financial...Is New 90 Day High Low • Dec 17New 90-day high: ₩4,905The company is up 41% from its price of ₩3,475 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 50% over the same period.分析記事 • Dec 03Are Wonik's (KOSDAQ:032940) Statutory Earnings A Good Reflection Of Its Earnings Potential?It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. However...Valuation Update With 7 Day Price Move • Dec 01Market bids up stock over the past weekAfter last week's 17% share price gain to ₩4,605, the stock is trading at a trailing P/E ratio of 34.3x, up from the previous P/E ratio of 29.3x. This compares to an average P/E of 25x in the Healthcare industry in Asia. Total return to shareholders over the past three years is a loss of 16%.Is New 90 Day High Low • Nov 16New 90-day high: ₩3,720The company is up 13% from its price of ₩3,290 on 18 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 7.0% over the same period.株主還元A032940KR HealthcareKR 市場7D4.1%0.3%-1.4%1Y-12.6%-26.1%99.2%株主還元を見る業界別リターン: A032940過去 1 年間で-26.1 % の収益を上げたKR Healthcare業界を上回りました。リターン対市場: A032940は、過去 1 年間で99.2 % のリターンを上げたKR市場を下回りました。価格変動Is A032940's price volatile compared to industry and market?A032940 volatilityA032940 Average Weekly Movement14.6%Healthcare Industry Average Movement10.4%Market Average Movement9.8%10% most volatile stocks in KR Market17.7%10% least volatile stocks in KR Market5.1%安定した株価: A032940の株価は、 KR市場と比較して過去 3 か月間で変動しています。時間の経過による変動: A032940の weekly volatility ( 15% ) は過去 1 年間安定していますが、依然としてKRの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト198190Cha Dong Yikwww.wonik.com韓国で半導体、貿易・流通、金融、化粧品、IT・電子部品、ロボット、レジャー事業を展開。同社は、基板上に回路を構築するプロセス装置、黒色平面および薄膜封止のドライエッチング装置、薄膜太陽電池装置、石英製品、セラミック、ランプ、半導体精密洗浄装置、前駆体、ガス供給・精製・監視システム、前駆体供給システム、配管工事を提供している。また、美容機器や手術器具などの医療機器、工業用原材料や照明関連製品、塗料、インク、接着剤、紙、人工大理石、電子材料、合成皮革・繊維などの化学製品、エンジニアリングプラスチックやシリコン製品、建築材料、脂質成分、商業用・工業用印刷・プリンターなどの取引や、関連する経営教育、技術サポート、ソフトウェアアップグレード、消耗部品の提供も行っている。また、中小ベンチャー企業への投資やコンサルティングサービス、ゴルフ場事業、ホテル事業、ガーデン事業も行っている。さらに、ハイブリッド集積回路とRF部品、ロボット工学アルゴリズムとロボットの試作、カスタマイズ、テスト、四足歩行ロボットAllegroDogを提供している。ウォニック・コーポレーションは1981年に設立され、韓国の城南市に本社を置く。もっと見るWonik Corporation 基礎のまとめWonik の収益と売上を時価総額と比較するとどうか。A032940 基礎統計学時価総額₩96.06b収益（TTM）₩9.48b売上高(TTM)₩151.10b10.8xPER（株価収益率0.7xP/SレシオA032940 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A032940 損益計算書（TTM）収益₩151.10b売上原価₩79.77b売上総利益₩71.32bその他の費用₩61.85b収益₩9.48b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）520.82グロス・マージン47.20%純利益率6.27%有利子負債／自己資本比率19.3%A032940 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/03 15:26終値2026/08/03 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Wonik Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩4,470, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 22% over the past three years.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,760, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 19x in the Healthcare industry in Asia. Total returns to shareholders of 103% over the past three years.
New Risk • Jun 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 47% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.3% net profit margin).
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩7,040, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 19x in the Healthcare industry in Asia. Total returns to shareholders of 75% over the past three years.
分析記事 • May 28We Think That There Are More Issues For Wonik (KOSDAQ:032940) Than Just Sluggish EarningsLast week's earnings announcement from Wonik Corporation ( KOSDAQ:032940 ) was disappointing to investors, with a...
New Risk • May 19New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩141.7b (US$94.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 46% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.6% net profit margin). Market cap is less than US$100m (₩141.7b market cap, or US$94.0m).
Valuation Update With 7 Day Price Move • Jul 29Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩4,470, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 22% over the past three years.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,760, the stock trades at a trailing P/E ratio of 14.9x. Average trailing P/E is 19x in the Healthcare industry in Asia. Total returns to shareholders of 103% over the past three years.
New Risk • Jun 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 47% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.3% net profit margin).
Valuation Update With 7 Day Price Move • Jun 02Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₩7,040, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 19x in the Healthcare industry in Asia. Total returns to shareholders of 75% over the past three years.
分析記事 • May 28We Think That There Are More Issues For Wonik (KOSDAQ:032940) Than Just Sluggish EarningsLast week's earnings announcement from Wonik Corporation ( KOSDAQ:032940 ) was disappointing to investors, with a...
New Risk • May 19New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩141.7b (US$94.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 46% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.6% net profit margin). Market cap is less than US$100m (₩141.7b market cap, or US$94.0m).
Valuation Update With 7 Day Price Move • May 13Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩9,520, the stock trades at a trailing P/E ratio of 15.1x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 140% over the past three years.
Valuation Update With 7 Day Price Move • Apr 20Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₩10,280, the stock trades at a trailing P/E ratio of 16.3x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 163% over the past three years.
New Risk • Apr 01New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 7.6% Last year net profit margin: 15% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 46% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.6% net profit margin).
お知らせ • Mar 17Wonik Corporation, Annual General Meeting, Mar 31, 2026Wonik Corporation, Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: av room, 20, pangyo-ro 255beon-gil, bundang-gu, gyeonggi-do, seongnam South Korea
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 26%After last week's 26% share price decline to ₩9,410, the stock trades at a trailing P/E ratio of 5.8x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 124% over the past three years.
分析記事 • Feb 10Wonik's (KOSDAQ:032940) Returns On Capital Not Reflecting Well On The BusinessThere are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
Valuation Update With 7 Day Price Move • Jan 06Investor sentiment improves as stock rises 32%After last week's 32% share price gain to ₩13,940, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 19x in the Healthcare industry in Asia. Total returns to shareholders of 240% over the past three years.
分析記事 • Dec 30Wonik Corporation (KOSDAQ:032940) Surges 47% Yet Its Low P/S Is No Reason For ExcitementWonik Corporation ( KOSDAQ:032940 ) shareholders have had their patience rewarded with a 47% share price jump in the...
New Risk • Dec 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 38% per year over the past 5 years. Minor Risk Large one-off items impacting financial results.
分析記事 • Dec 26We Think Wonik (KOSDAQ:032940) Is Taking Some Risk With Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Nov 21Shareholders In Wonik (KOSDAQ:032940) Should Look Beyond Earnings For The Full StoryThe latest earnings release from Wonik Corporation ( KOSDAQ:032940 ) disappointed investors. We did some analysis and...
Reported Earnings • Nov 20Third quarter 2025 earnings released: EPS: ₩455 (vs ₩295 in 3Q 2024)Third quarter 2025 results: EPS: ₩455 (up from ₩295 in 3Q 2024). Revenue: ₩39.6b (up 18% from 3Q 2024). Net income: ₩8.28b (up 55% from 3Q 2024). Profit margin: 21% (up from 16% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Nov 12Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩8,720, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 144% over the past three years.
分析記事 • Oct 27The Market Lifts Wonik Corporation (KOSDAQ:032940) Shares 40% But It Can Do MoreThe Wonik Corporation ( KOSDAQ:032940 ) share price has done very well over the last month, posting an excellent gain...
Valuation Update With 7 Day Price Move • Oct 27Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩9,300, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 207% over the past three years.
分析記事 • Oct 24The Returns On Capital At Wonik (KOSDAQ:032940) Don't Inspire ConfidenceIf you're looking for a multi-bagger, there's a few things to keep an eye out for. One common approach is to try and...
分析記事 • Aug 28Is Wonik (KOSDAQ:032940) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩6,980, the stock trades at a trailing P/E ratio of 4.8x. Average trailing P/E is 43x in the Healthcare industry in South Korea. Total returns to shareholders of 88% over the past three years.
New Risk • Aug 27New major risk - Revenue and earnings growthEarnings have declined by 34% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 34% per year over the past 5 years. Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩116.3b market cap, or US$83.4m).
分析記事 • Jul 31Slammed 32% Wonik Corporation (KOSDAQ:032940) Screens Well Here But There Might Be A CatchThe Wonik Corporation ( KOSDAQ:032940 ) share price has softened a substantial 32% over the previous 30 days, handing...
分析記事 • Jul 23Returns On Capital At Wonik (KOSDAQ:032940) Paint A Concerning PictureIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₩7,710, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 20x in the Healthcare industry in Asia. Total returns to shareholders of 111% over the past three years.
分析記事 • May 29Fewer Investors Than Expected Jumping On Wonik Corporation (KOSDAQ:032940)You may think that with a price-to-sales (or "P/S") ratio of 0.6x Wonik Corporation ( KOSDAQ:032940 ) is a stock worth...
Valuation Update With 7 Day Price Move • May 29Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩4,620, the stock trades at a trailing P/E ratio of 3x. Average trailing P/E is 39x in the Healthcare industry in South Korea. Negligible returns to shareholders over past three years.
New Risk • May 23New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 122% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩68.0b market cap, or US$49.5m).
分析記事 • Apr 01There May Be Underlying Issues With The Quality Of Wonik's (KOSDAQ:032940) EarningsWonik Corporation's ( KOSDAQ:032940 ) robust earnings report didn't manage to move the market for its stock. We did...
お知らせ • Mar 13Wonik Corporation, Annual General Meeting, Mar 31, 2025Wonik Corporation, Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: av room, 20, pangyo-ro 255beon-gil, bundang-gu, gyeonggi-do, seongnam South Korea
分析記事 • Feb 21Market Might Still Lack Some Conviction On Wonik Corporation (KOSDAQ:032940) Even After 35% Share Price BoostWonik Corporation ( KOSDAQ:032940 ) shareholders have had their patience rewarded with a 35% share price jump in the...
分析記事 • Feb 21Market Might Still Lack Some Conviction On Wonik Corporation (KOSDAQ:032940) Even After 35% Share Price BoostWonik Corporation ( KOSDAQ:032940 ) shareholders have had their patience rewarded with a 35% share price jump in the...
New Risk • Feb 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩85.0b market cap, or US$59.3m).
New Risk • Dec 09New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩56.4b market cap, or US$39.6m).
New Risk • Nov 22New major risk - Revenue and earnings growthEarnings have declined by 8.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.8% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩61.8b market cap, or US$44.1m).
分析記事 • Nov 01The Market Doesn't Like What It Sees From Wonik Corporation's (KOSDAQ:032940) Revenues YetWhen you see that almost half of the companies in the Healthcare industry in Korea have price-to-sales ratios (or...
お知らせ • Aug 22Horizon Ltd. acquired an additional 38.18% stake in Wonik Corporation (KOSDAQ:A032940) from Lee Yong Han.Horizon Ltd. acquired an additional 38.18% stake in Wonik Corporation (KOSDAQ:A032940) on August 20, 2024.Horizon now holds 46.33% stake in Wonik. The transaction will be financed through equity investment of KRW 5 billion and senior debt of KRW 21.29 billion. Horizon Ltd. completed the acquisition of an additional 38.18% stake in Wonik Corporation (KOSDAQ:A032940) from Lee Yong Han on August 20, 2024.
分析記事 • Aug 12Is Wonik (KOSDAQ:032940) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Jun 18Wonik Corporation's (KOSDAQ:032940) Price Is Right But Growth Is Lacking After Shares Rocket 42%Wonik Corporation ( KOSDAQ:032940 ) shareholders have had their patience rewarded with a 42% share price jump in the...
分析記事 • May 21Estimating The Fair Value Of Wonik Corporation (KOSDAQ:032940)Key Insights Wonik's estimated fair value is ₩4,480 based on 2 Stage Free Cash Flow to Equity With ₩5,120 share price...
New Risk • May 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (₩93.1b market cap, or US$68.5m).
Valuation Update With 7 Day Price Move • Feb 02Investor sentiment improves as stock rises 24%After last week's 24% share price gain to ₩4,375, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 24x in the Healthcare industry in Asia. Total loss to shareholders of 6.5% over the past three years.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 1 independent director (6 non-independent directors). Chairman Yong-Han Lee was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jun 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩3,565, the stock trades at a trailing P/E ratio of 2.6x. Average trailing P/E is 17x in the Healthcare industry in Asia. Total loss to shareholders of 9.9% over the past three years.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 1 highly experienced director. 1 independent director (6 non-independent directors). Chairman Yong-Han Lee was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Buying Opportunity • Feb 15Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 5.5%. The fair value is estimated to be ₩5,083, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.0% per annum over the last 3 years. The company has become profitable over the last year.
Buying Opportunity • Jan 25Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be ₩5,071, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.0% per annum over the last 3 years. The company has become profitable over the last year.
分析記事 • May 03I Ran A Stock Scan For Earnings Growth And Wonik (KOSDAQ:032940) Passed With EaseFor beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Is New 90 Day High Low • Feb 26New 90-day low: ₩4,265The company is down 3.0% from its price of ₩4,395 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare industry, which is up 9.0% over the same period.
分析記事 • Feb 21Reflecting on Wonik's (KOSDAQ:032940) Share Price Returns Over The Last Five YearsWhile not a mind-blowing move, it is good to see that the Wonik Corporation ( KOSDAQ:032940 ) share price has gained...
Is New 90 Day High Low • Jan 26New 90-day high: ₩5,150The company is up 51% from its price of ₩3,415 on 28 October 2020. The South Korean market is up 36% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 72% over the same period.
分析記事 • Jan 25Is Wonik (KOSDAQ:032940) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Jan 07New 90-day high: ₩5,020The company is up 44% from its price of ₩3,480 on 08 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 56% over the same period.
分析記事 • Dec 29Wonik Corporation (KOSDAQ:032940) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?Wonik's (KOSDAQ:032940) stock is up by a considerable 36% over the past three months. But the company's key financial...
Is New 90 Day High Low • Dec 17New 90-day high: ₩4,905The company is up 41% from its price of ₩3,475 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare industry, which is up 50% over the same period.
分析記事 • Dec 03Are Wonik's (KOSDAQ:032940) Statutory Earnings A Good Reflection Of Its Earnings Potential?It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. However...
Valuation Update With 7 Day Price Move • Dec 01Market bids up stock over the past weekAfter last week's 17% share price gain to ₩4,605, the stock is trading at a trailing P/E ratio of 34.3x, up from the previous P/E ratio of 29.3x. This compares to an average P/E of 25x in the Healthcare industry in Asia. Total return to shareholders over the past three years is a loss of 16%.
Is New 90 Day High Low • Nov 16New 90-day high: ₩3,720The company is up 13% from its price of ₩3,290 on 18 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 7.0% over the same period.
